Arvaya Healthcare sets up insurance arm, eyes rights issue for expansion

By Vivian Lin · September 23, 2026, 12:43 PM · 3 mins read

Arvaya Healthcare is changing course with a new insurance broking unit and a push into gastroenterology. Shareholders now wait for details on a key rights issue to fund these plans.

Arvaya Healthcare shareholders face a turning point. The company is moving fast, launching an insurance broking subsidiary and preparing a rights issue to fund its next stage of growth.

The 41st Annual General Meeting on September 21, 2026, marked a clear break from the past. Management dropped the old name and adopted "Arvaya Healthcare Limited." This was more than a rebrand. It signaled a shift to a broader healthcare focus. The biggest move: setting up Arvaya Insurance Broking Private Limited as a wholly-owned subsidiary. This puts Arvaya into the insurance broking business for the first time. According to ScanX Trade reporting, e-voting on AGM resolutions ran from September 18 to 20, with the meeting itself on September 21.

On September 17, 2026, Arvaya Insurance Broking Private Limited was officially registered as a wholly owned subsidiary, marking the company's formal entry into the insurance broking segment.

Arvaya is not stopping there. The company is also moving to buy Sushoda Institute of Gastroenterology Private Limited. This would anchor its push into specialized medical services. The plan is to diversify revenue and cut reliance on old business lines. Arvaya, once known as Bijoy Hans Limited, confirmed its new name and direction in official AGM market summaries.

To pay for these moves, Arvaya is lining up a rights issue. Existing shareholders will be asked to put in new capital. The company has not yet shared the terms, price, or record date. Investors are waiting for the next official update. The timing and structure of the rights issue matter. They will shape shareholder value and decide if Arvaya can pull off its acquisition and integration plans. Public filings show the rights issue proceeds are set aside for buying intellectual property from DEFIB Institute of Health Solutions LLP and for supporting the new business structure. The exact details are still under wraps.

At the AGM, shareholders signed off on the audited financials for FY 2025-26. They reappointed Mr. Kaushal Uttam Shah as Managing Director. They also approved key related party deals, including the DEFIB IP acquisition. These steps clear the way for Arvaya’s new strategy. The related party transactions approved at the meeting total ₹390 crore for FY27. The DEFIB IP deal is capped at up to ₹10 crore, as shown in AGM market summaries.

The acquisition of IP from DEFIB Institute of Health Solutions LLP was classified as a material related party transaction due to the involvement of Bidari Kotresh Anilkumar as a designated partner at DEFIB, necessitating shareholder approval at the AGM.

ScanX TradeMarket News Portal

The road ahead is not simple. Adding insurance broking and gastroenterology brings new challenges and risks. Investors should watch the timeline for closing the Sushoda Institute deal and the final rights issue terms. Both will show if this strategy pays off or leaves Arvaya exposed.

Arvaya Healthcare is betting on reinvention and new business lines. In healthcare, standing still is not an option. The next few months will show if this push for growth can last, or if the company is moving too fast. For now, all eyes are on Arvaya’s next move.

Topics:

Biotechnology Newsroom

Vivian Lin

Vivian Lin is Biotech Markets & Transactions Editor at GenoMethods, covering licensing agreements, M&A, biotech financing, company pipelines, strategic partnerships and cross-border transactions. Her reporting connects deal structure and company strategy with the scientific and clinical evidence underlying each biotechnology asset.